A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor for lysosomal degradation. As the interaction promotes elevated plasma LDL-C levels,...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M.G. Princen, James Bonnar, Benny J. Evison
स्वरूप:	लेख
भाषा:	English
प्रकाशित:	Elsevier 2022-11-01
श्रृंखला:	Journal of Lipid Research
विषय:	PCSK9 cardiovascular disease hypercholesterolemia small-molecule lipoproteins apolipoproteins
ऑनलाइन पहुंच:	http://www.sciencedirect.com/science/article/pii/S0022227522001262

समान संसाधन

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
द्वारा: Jean-Philippe Drouin-Chartier, और अन्य
प्रकाशित: (2017-06-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
द्वारा: A O Averkova
प्रकाशित: (2017-09-01)

Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure
द्वारा: Khalid Al-Waili, और अन्य
प्रकाशित: (2013-01-01)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
द्वारा: Arianna Toscano, और अन्य
प्रकाशित: (2022-04-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
द्वारा: S. Yu. Volkova, और अन्य
प्रकाशित: (2023-03-01)

PCSK9: A New Target for Lipid-Lowering Therapy
द्वारा: Nutjaree Jeenduang
प्रकाशित: (2014-04-01)

Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers
द्वारा: Maryam Mahjoubin-Tehran, और अन्य
प्रकाशित: (2024-05-01)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
द्वारा: Tsuyoshi Yamamoto, और अन्य
प्रकाशित: (2012-01-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
द्वारा: Blom DJ, और अन्य
प्रकाशित: (2016-05-01)

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis
द्वारा: Dong Liu, और अन्य
प्रकाशित: (2024-09-01)

VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
द्वारा: Madeline M. Vroom, और अन्य
प्रकाशित: (2024-02-01)

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
द्वारा: Li Li, और अन्य
प्रकाशित: (2018-09-01)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
द्वारा: Dipti Athavale, और अन्य
प्रकाशित: (2018-10-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
द्वारा: S. K. Zyryanov, और अन्य
प्रकाशित: (2022-12-01)

Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach
द्वारा: Alessandro Di Minno, और अन्य
प्रकाशित: (2021-08-01)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
द्वारा: Kosmas CE, और अन्य
प्रकाशित: (2020-12-01)

Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State
द्वारा: Georgios Louloudis, और अन्य
प्रकाशित: (2021-09-01)

Case report: Unusual coexistence between familial hypercholesterolemia and familial hypobetalipoproteinemia
द्वारा: Kei Sasaki, और अन्य
प्रकाशित: (2022-08-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
द्वारा: Piotr Pęczek, और अन्य
प्रकाशित: (2021-05-01)

The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up
द्वारा: Maryam Moshkani Farahani, और अन्य
प्रकाशित: (2024-09-01)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
द्वारा: Marina Blanco-Ruiz, और अन्य
प्रकाशित: (2021-11-01)

Gene Therapy Targeting <i>PCSK9</i>
द्वारा: Julius L. Katzmann, और अन्य
प्रकाशित: (2022-01-01)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
द्वारा: Takahito Doi, और अन्य
प्रकाशित: (2021-02-01)

PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
द्वारा: Victoria Marco-Benedí, और अन्य
प्रकाशित: (2024-09-01)

PCSK9: NEW VICTORY AND HORIZONS
द्वारा: M. O. Smolina, और अन्य
प्रकाशित: (2018-09-01)

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo
द्वारा: Elise F. Villard, PhD, और अन्य
प्रकाशित: (2016-10-01)

Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects
द्वारा: María Molina-Vega, और अन्य
प्रकाशित: (2020-05-01)

Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis
द्वारा: Yi-Ting Huang, और अन्य
प्रकाशित: (2022-04-01)

PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
द्वारा: Natalia Pauli, और अन्य
प्रकाशित: (2020-07-01)

MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes
द्वारा: Xuemei Chen, और अन्य
प्रकाशित: (2024-11-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
द्वारा: Simon Rauterberg, और अन्य
प्रकाशित: (2025-01-01)

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries
द्वारा: Marcello Arca, और अन्य
प्रकाशित: (2023-11-01)

Identification of a novel LDLR p.Glu179Met variant in Thai families with familial hypercholesterolemia and response to treatment with PCSK9 inhibitor
द्वारा: Burabha Pussadhamma, और अन्य
प्रकाशित: (2024-03-01)

Expression of a PCSK9 Gain-of-Function Mutation in C57BL/6J Mice to Facilitate Angiotensin II-Induced AAAs
द्वारा: Hisashi Sawada, और अन्य
प्रकाशित: (2022-06-01)

Competing Genetic Traits and Their Influence on LDL Cholesterol Concentration in Familial Hypercholesterolemia
द्वारा: Christopher Song, MD, और अन्य
प्रकाशित: (2024-01-01)

PCSK9 Inhibitors: The Evolving Future
द्वारा: Bijay Mukesh Jeswani, और अन्य
प्रकाशित: (2024-11-01)

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
द्वारा: Harold E. Bays, और अन्य
प्रकाशित: (2017-08-01)

Failure of lipid control by PCSK9 inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report
द्वारा: Ziyue Zhang, और अन्य
प्रकाशित: (2024-03-01)

Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity
द्वारा: Carmen Lammi, और अन्य
प्रकाशित: (2022-03-01)

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke[S]
द्वारा: Estelle Rousselet, और अन्य
प्रकाशित: (2011-07-01)